Showing 3541-3550 of 6035 results for "".
- Modular Super-Enhancer Controls Retinal Developmenthttps://modernod.com/news/modular-super-enhancer-controls-retinal-development/2480571/Scientists at St. Jude Children’s Research Hospital identified distinct functions for regions of a super-enhancer that controls gene expression during retina formation, calling it a ‘modular’ super-enhancer. Enhancers are regions of DNA that do not
- Glaukos’ iDose TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 36 Months in Phase 2b Studyhttps://modernod.com/news/glaukos-idose-tr-demonstrates-sustained-iop-reduction-and-favorable-safety-profile-over-36-months-in-phase-2b-study/2480567/Glaukos announced that its iDose TR sustained-release travoprost implant continued to provide sustained substantial reductions in IOP in a 36-month analysis of the phase 2b clinical trial conducted under a U.S. investigational new drug (IND) protocol. <
- Alcon to Launch Dailies Total1 Contact Lenses in the U.S. for Patients with Astigmatismhttps://modernod.com/news/alcon-to-launch-dailies-total1-contact-lenses-in-the-us-for-patients-with-astigmatism/2480565/
- EyePoint Pharmaceuticals Announces 2022 Clinical Plans and Highlights Recent Corporate and Clinical Achievementshttps://modernod.com/news/eyepoint-pharmaceuticals-announces-2022-clinical-plans-and-highlights-recent-corporate-and-clinical-achievements/2480554/EyePoint Pharmaceuticals announced its 2022 clinical pipeline plans and highlighted recent corporate achievements driven by its lead pipeline candidate, EYP-1901, a potential 6-month intravitreal treatment targeting wet age-related macular degeneration (AMD).
- Ray Therapeutics Closes $6M Seed Financing to Advance Novel Optogenetics Platform to Treat Blinding Diseaseshttps://modernod.com/news/ray-therapeutics-closes-6m-seed-financing-to-advance-novel-optogenetics-platform-to-treat-blinding-diseases/2480549/Ray Therapeutics, a developer of optogenetic gene therapies for patients with blinding diseases, announced the closing of a $6 million seed financing round, led by 4BIO Capital. The funding will be used to advance its optogenetic therapy, Ray-001, into clinical trials in retinitis
- Rayner Appoints Ophthalmic Leaders as Strategic Advisors and is Awarded IDE for Trifocal IOLshttps://modernod.com/news/rayner-appoints-esteemed-ophthalmic-leaders-as-strategic-advisors-and-is-awarded-ide-for-trifocal-iols/2480533/Rayner has announced the appointment of Eric Donnenfeld, MD; Kerry Solomon, MD; Vance Thompson, MD; and Jim Mazzo as strategic advisors to the business, with a
- Sight Sciences Receives FDA 510(k) Clearance of the TearCare System for Treatment of Meibomian Gland Dysfunction (MGD)https://modernod.com/news/sight-sciences-receives-fda-510k-clearance-of-the-tearcare-system-for-treatment-of-meibomian-gland-dysfunction-mgd/2480531/Sight Sciences announced FDA 510(k) clearance of the TearCare System for the treatment of meibomian gland dysfunction (MGD), the leading cause of dry eye disease (DED). The indication clears TearCare for the application of localized heat therapy in adult patients with
- ImprimisRx to Assume Full Responsibility for US Sales and Marketing Activities for Dexycuhttps://modernod.com/news/imprimisrx-to-assume-full-responsibility-for-us-sales-and-marketing-activities-for-dexycu/2480499/EyePoint Pharmaceut
- Ophthalmic Sciences Unveils AI Contactless Device for Measuring IOPhttps://modernod.com/news/ophthalmic-sciences-unveils-ai-contactless-device-for-measuring-iop/2480487/
- VSY Biotechnology Discovers How to Connect the Golden Ratio Concept to its New Intraocular Lens Technologyhttps://modernod.com/news/vsy-biotechnology-gmbh-discovers-how-to-connect-the-golden-ratio-concept-to-its-new-intraocular-lens-technology/2480479/